Comparison of Cardiovascular Benefits of Bariatric Surgery and Abdominal Lipectomy

  • Petra RocicEmail author
Hypertension and Obesity (Efrain Reisin, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertension and Obesity


Purpose of Review

The purpose of this review is to examine recent evidence supporting effectiveness of bariatric surgery and abdominal lipectomy as interventional strategies aimed at reduction in incidence of cardiovascular disease (CVD) and related morbidity and mortality in obese and metabolic syndrome patients.

Recent Findings

While several studies show reduction in CVD risk factors in patients who have undergone both the Roux-en-Y gastric bypass and sleeve gastrectomy, very few demonstrate actual improvements in cardiovascular function, or a decrease in CVD events or CVD-related mortality. Consequently, the cardiovascular benefits of the less invasive sleeve gastrectomy in comparison to the gastric bypass are also unclear. Striking new data on large patient samples demonstrate significant positive correlation between gastric bypass and CVD risk factor reduction only in patients who are diabetic or > 50 years of age at the time of surgery, with no significant differences in non-diabetic and younger patients and with significant side effects. On the other hand, a markedly less invasive removal of abdominal subcutaneous adipose tissue via lipectomy consistently and significantly improved CVD risk factors as well as cardiovascular function in the very few studies available.


Overall, neither the potential nor the definitive cardiovascular benefits of either of the commonly used bariatric surgical or the various lipectomy procedures have been adequately explored. Future basic science and clinical studies have the opportunity to understand the mechanisms and long-term consequences of both approaches and develop personalized approaches with higher benefit to side effect ratios.


Gastric bypass Sleeve gastrectomy Abdominal lipectomy Cardiovascular disease (CVD) 


Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

All animal experiments referred to in this review were performed in accordance with the Animal Welfare Act and were approved by the IACUCs of New York Medical College and the University of South Alabama.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–96.CrossRefGoogle Scholar
  2. 2.
    Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004;140:992–1000.CrossRefGoogle Scholar
  3. 3.
    Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925–32.CrossRefGoogle Scholar
  4. 4.
    D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.CrossRefGoogle Scholar
  5. 5.
    Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;288:1–8.Google Scholar
  6. 6.
    Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang ARCS, Chiuve SECM, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee: heart disease and stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.CrossRefGoogle Scholar
  7. 7.
    Angrisani L, Santonicola A, Iovino P, Vitiello A, Zundel N, Buchwald H, et al. Bariatric surgery and Endoluminal procedures: IFSO worldwide survey 2014. Obes Surg. 2017;27:2279–89.CrossRefGoogle Scholar
  8. 8.
    Goday A, Benaiges D, Parri A, Ramón JM, Flores-Le Roux JA, Pedro Botet J. Obemar group: can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient? Surg Obes Relat Dis. 2014;10:871–6.CrossRefGoogle Scholar
  9. 9.
    Pereira PR, Guimarães M, Morais T, Pereira SS, Nora M, Monteiro MP. Diabetic and elder patients experience superior cardiovascular benefits after gastric bypass induced weight loss. Front Endocrinol. 2018;9.
  10. 10.
    • Eliasson B, Liakopoulos V, Franzén S, Näslund I, Svensson AM, Ottosson J, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol. 2015;3:847–54. This is one of the two studies which evaluated the effect of gastric bypass on CVD outcomes (CVD death, fatal and non-fatal myocardial infarction and all-cause death), thus providing valuable data with respect to functional effectiveness of gastric bypass.CrossRefGoogle Scholar
  11. 11.
    Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Swedish obese subjects study: effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRefGoogle Scholar
  12. 12.
    Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.CrossRefGoogle Scholar
  13. 13.
    Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.CrossRefGoogle Scholar
  14. 14.
    Inge TH, Jenkins TM, Xanthakos SA, Dixon JB, Daniels SR, Zeller MH, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol. 2017;5:165–73.CrossRefGoogle Scholar
  15. 15.
    • Lent MR, Benotti PN, Mirshahi T, Gerhard GS, Strodel WE, Petrick AT, et al. All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes. Diabetes Care. 2017;40:1379–85. This study on a large sample of patients presents striking new data demonstrating that while the Reux-en-Y gastric bypass confers large CVD benefits in patients who are diabetic at the time of surgery, minimal or no benefit is observed in non-diabetic patients. Furthermore, the study finds, non-CVD, but gastric bypass-related mortality is a significant complication of this intervention.CrossRefGoogle Scholar
  16. 16.
    Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24:437–55.CrossRefGoogle Scholar
  17. 17.
    Romeo S, Maglio C, Burza MA, Pirazzi C, Sjöholm K, Jacobson P, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;35:2613–7.CrossRefGoogle Scholar
  18. 18.
    Wei JH, Chou RH, Huang PH, Lee WJ, Chen SC, Lin SJ. Metabolic surgery ameliorates cardiovascular risk in obese diabetic patients: influence of different surgical procedures. Surg Obes Relat Dis. 2018;14:1832–40.CrossRefGoogle Scholar
  19. 19.
    Yang P, Chen B, Xiang S, Lin XF, Luo F, Li W. Long-term outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for morbid obesity: results from a meta-analysis of randomized controlled trials. Surg Obes Relat Dis. 2019;S1550-7289:31203–6.Google Scholar
  20. 20.
    Kang JH, Le QA. Effectiveness of bariatric surgical procedures: a systematic review and network meta-analysis of randomized controlled trials. Medicine. 2017;96:e8632.CrossRefGoogle Scholar
  21. 21.
    • Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319:241–54. This is a large clinical trial which demonstrated that at 5 year follow-up, neither weight loss nor CVD risk factors (type II diabetes, dyslipidemia, hypertension) were equivalent between gastric bypass vs. sleeve gastrectomy groups of patients.CrossRefGoogle Scholar
  22. 22.
    Blanco DG, Funes DR, Giambartolomei G, Lo Menzo E, Szomstein S, Rosenthal RJ. Laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass in cardiovascular risk reduction: a match control study. Surg Obes Relat Dis. 2018;S1550-7289:31148–51.Google Scholar
  23. 23.
    Gómez-Martin JM, Aracil E, Galindo J, Escobar-Morreale HF, Balsa JA, Botella-Carretero JI. Improvement in cardiovascular risk in women after bariatric surgery as measured by carotid intima-media thickness: comparison of sleeve gastrectomy versus gastric bypass. Surg Obes Relat Dis. 2017;13:848–54.CrossRefGoogle Scholar
  24. 24.
    Hallersund P, Sjöström L, Olbers T, Lönroth H, Jacobson P, Wallenius V, et al. Gastric bypass surgery is followed by lowered blood pressure and increased diuresis - long term results from the Swedish obese subjects (SOS) study. PLoS One. 2012;7:e49696.CrossRefGoogle Scholar
  25. 25.
    Giugliano G, Nicoletti G, Grella E, Giugliano F, Esposito K, Scuderi N, et al. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg. 2004;57:190–4.CrossRefGoogle Scholar
  26. 26.
    Vinci V, Valaperta S, Klinger M, Montanelli A, Specchia C, Forcellini D, et al. Metabolic implications of surgical fat removal: increase of adiponectin plasma levels after reduction Mammaplasty and abdominoplasty. Ann Plast Surg. 2016;76:700–4.CrossRefGoogle Scholar
  27. 27.
    Cuomo R, Russo F, Sisti A, Nisi G, Grimaldi L, Brandi C, et al. Abdominoplasty in mildly obese patients (BMI 30-35 kg/m2): metabolic, biochemical and complication analysis at one year. In Vivo. 2015;29:757–61.PubMedGoogle Scholar
  28. 28.
    • Marfella R, Grella R, Rizzo MR, Barbieri M, Grella R, Ferraraccio F, et al. Role of subcutaneous abdominal fat on cardiac function and proinflammatory cytokines in premenopausal obese women. Ann Plast Surg. 2009;63:490–5. This study demonstrated significant improvement not only in circulating adipokines and inflammatory cytokines, but, importantly, also in the myocardial performance index measured by echocardiography 2 months after abdominoplasty (surgical removal of subcutaneous abdominal adipose tissue), thus demonstrating that lipectomy does improve functional cardiovascular outcomes.CrossRefGoogle Scholar
  29. 29.
    Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139:448–55.CrossRefGoogle Scholar
  30. 30.
    Sailon AM, Wasserburg JR, Kling RR, Pasick CM, Taub PJ. Influence of large-volume liposuction on metabolic and cardiovascular health: a systematic review. Ann Plast Surg. 2017;79:623–30.CrossRefGoogle Scholar
  31. 31.
    Crahay FX, Nizet JL. Metabolic and cardiovascular consequences of suction-assisted lipectomy: systematic review. Ann Chir Plast Esthet. 2016;61:270–86.CrossRefGoogle Scholar
  32. 32.
    • Kranendonk ME, van Herwaarden JA, Stupkova T, de Jager W, Vink A, Moll FL, et al. Inflammatory characteristics of distinct abdominal adipose tissue depots relate differently to metabolic risk factors for cardiovascular disease: distinct fat depots and vascular risk factors. Atherosclerosis. 2015;239:419–27. This study demonstrated key morphological and functional differences in different fat depots with respect to production of adipokines known to mediate CVD in humans, thus emphasizing the need for utilizing this knowledge in further exploration of potential for lipectomy as an interventional strategy for reduction and/or delay of incidence of CVD in obese and metaboic syndrome patients.CrossRefGoogle Scholar
  33. 33.
    Hutcheson R, Terry R, Chaplin J, Smith E, Musiyenko A, Russell JC, et al. MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2013;33:727–36.CrossRefGoogle Scholar
  34. 34.
    Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, et al. 20-HETE signals through G-protein-coupled receptor GPR75 (Gq) to affect vascular function and trigger hypertension. Circ Res. 2017;120:1776–88.CrossRefGoogle Scholar
  35. 35.
    Rocic P, Schwartzman ML. 20-HETE in the regulation of vascular and cardiac function. Pharmacol Ther. 2018;192:74–87.CrossRefGoogle Scholar
  36. 36.
    Soler A, Hunter I, Joseph G, Hutcheson R, Hutcheson B, Yang J, et al. Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation. J Mol Cell Cardiol. 2018;117:88–99.CrossRefGoogle Scholar
  37. 37.
    Peterson SJ, Vanella L, Gotlinger K, Jiang H, Singh SP, Sodhi K, et al. Oxidized HDL is a potent inducer of adipogenesis and causes activation of the Ang-II and 20-HETE systems in human obese females. Prostaglandins Other Lipid Mediat. 2016;123:68–77.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacologyNew York Medical CollegeValhallaUSA

Personalised recommendations